[Webinar] How to recruit immune cells against tumor? Bispecific compounds are the key for new oncology therapeutic strategy

[Webinar] How to recruit immune cells against tumor? Bispecific compounds are the key for new oncology therapeutic strategy

[Webinar] How to recruit immune cells against tumor? Bispecific compounds are the key for new oncology therapeutic strategy

18 June 2020
5pm CEST


Bispecific compounds are now considered as a new therapeutic strategy in oncology.
A number of bispecific compounds are under development at various clinical stages and two have already been approved. Given that these compounds are antibody-like and species-specific, new tools are subsequently needed to characterize them on a preclinical level.
From in vitro models up to in vivo humanized mouse models, including imaging as an option to track immune cells, all of these strategies will be exemplified in the context of compounds that recruit immune cells against tumors.

Key learning objectives

  • In vitro characterization
  • In vitro pharmacology
  • In vivo pharmacology (incl. Imaging) 

Discover our speaker Jean-François Mirjolet

Jean-François has been working for Oncodesign for 17 years. Jean-François obtained his Ph.D. from the University of Nancy, France, in cellular pharmacology of anticancer drugs, followed by post-doctoral position at the IRIBHM, Brussels, Belgium, in chemokines and chemokine receptors implication in cancer cell migration. At Oncodesign, Jean-François started as a study director and then the position of Technology Director, directly supporting our Business Development activity and working closely with our clients to select the most appropriate study designs for the evaluation of their therapies through preclinical studies. Jean-François has been the Head of the In Vitro Sciences Department since 2018. In this capacity, he manages both services and R&D related in vitro activities.

View the presentation on line

[Press Release] Oncodesign reports its first-half revenue and a strong increase in its cash position at June 30, 2020

23/07/2020

DOWNLOAD

[WEBINARS] SUMMERTIME CATCH-UP PROGRAM

[WEBINARS] SUMMERTIME  CATCH-UP PROGRAM

Summertime is here to catch up with scientific innovation!

Find our topical webinars on our dedicated webinar channel. They shed light in our expertise in drug discovery in oncology and inflammation therapeutic areas. Oncodesign guides you to conceive, optimize and evaluate your compound efficacy and developability from Hit finding to IND.

I become an expert

[Webinar] NEW INTERACTIVE PANEL WEBINAR] DRIVE™: Brothers in Arms to support small molecule drug discovery from Hit to IND

View the presentation on line [Webinar] [NEW INTERACTIVE PANEL WEBINAR] DRIVE™ : Brothers in Arms to support small molecule drug discovery from Hit to INDView the presentation on line[Webinar] [NEW INTERACTIVE PANEL WEBINAR] DRIVE™ : Brothers in Arms to support small molecule drug discovery from Hit to IND

View the presentation on line [Webinar] NEW INTERACTIVE PANEL WEBINAR] DRIVE™: Brothers in Arms to support small molecule drug discovery from Hit to IND

7 July 2020
5 pm CEST


Outsourcing drug discovery has become an overwhelmingly accepted approaches across the pharmaceutical industry from virtual biotech to large pharmaceutical companies as part of the globalization process. It does represent a cost-effective opportunity to access specialized technologies and expert scientist resources having a broad knowledge of pharmaceutical drug discovery development. Oncodesign’s objective with DRIVE™ offer is to provide its customers with the best possible options and state-of-the-art technologies to progress their drug discovery in the shortest possible time with the highest quality.

Oncodesign is doing so by setting up under a single leadership, privileged partnering with selected and trusted companies sharing the same values of innovation and quality as its own. 
Hits finding and validation are important phases in early drug discovery. With Program, Oncodesign is providing DNA encoded libraries, fragments screening along with Hit validation using NanoDSF, MST, SPR, ITC and Structural Biology (Cryo-EM and X-Ray crystallography) supported by artificial intelligence. 

Key learning objectives

  • Introduction to a solution provider from hits finding to IND filing
  • Advantages of drug discovery integrated provider vs silos approach
  • Special focus on Hit identification and validation across DNA encoded libraries, Artificial Intelligence, Biophsysics and Biostructures  

Discover our speakers

View the presentation on line